Cognitive neuropeptide

Semax

Semax is a synthetic heptapeptide analog of the ACTH 4-10 fragment.1 FDA's 2026 briefing did not find a pharmacokinetic study of it in humans by any route.1

Moderate evidenceGet the app

Level after one dose

Semax after one dose: 50% at ~3 min, 25% at 6 min, 12.5% at 9 min.

Drawn from the half-life in the app's model, ~3 min. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

3%The joint 22nd most tracked compound in Milligram: of people who track compounds in Milligram logged Semax in the last 90 days.

Schedule

  1. Daily60%
  2. Every other day33%
  3. Twice a week3%
  4. Weekly3%
  5. Less often0%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 250 and 500 mcg per dose; the median was 400 mcg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging Semax who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

2

Overview

Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro.1 FDA's briefing, citing Kolomin and colleagues (2013), describes the ACTH 4-10 fragment as "devoid of the hormonal corticotropic and melanotropic properties but retains the neurobehavioral properties of the full-length ACTH protein".1 The same briefing states: "Semax is a registered drug in Russia and is available as 0.1% and 1% nasal drops".1 It also states that, for semax (free base) and semax acetate, "neither is a component of an FDA-approved drug".1

FDA's reviewers wrote that references on cerebral ischemia "were articles published in Russian" and that "Because the full references were not available in English, these references were not considered as part of this evaluation".1 The Russian-language human reports below are quoted from the English summary held in the PubMed record. Funding, sponsor ties and the authors' own limitations are stated where a record gives them.

The evidence badge reads Moderate Evidence; that is the app's own grade. FDA's reviewers concluded for the three uses they assessed: "There is insufficient evidence to support the effectiveness for semax (free base) or semax acetate for cerebral ischemia, migraine, or trigeminal neuralgia".1

FDA's briefing summarises the nonclinical work in rodents: "semax is a substance that exhibits pleiotropism", with neuroprotective and neurotrophic, anticoagulant and antithrombotic, analgesic and antidepressant- and anxiolytic-like findings, "Acting through poorly understood mechanisms of action".1

Neurotrophin signalling in rats

Dolotov and colleagues (Institute of Molecular Genetics, Russian Academy of Sciences), Brain Research, 2006, report that "a single application of Semax (50 microg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels" in the rat hippocampus.2 Agapova and colleagues, Neuroscience Letters, 2007, gave male Wistar rats a single intranasal application of 50 µg/kg and report increased neurotrophin gene expression in the hippocampus, but also that "Ngf gene expression decreased in rat frontal cortex".3

Enkephalinase, serotonin and dopamine findings

Kost and colleagues, Bioorganicheskaia Khimiia, 2001, report a "dose-dependent effect" of Semax on the enkephalin-degrading enzymes of human serum, with an IC50 of 10 microM; this is an in vitro assay on human serum enzymes, not a study in people.4 FDA adds that in rats naloxone "did not prevent the analgesic effect of semax", while cyproheptadine blocked it, and that intranasal doses "were unable to induce analgesia" in one rat study.1 FDA also calls it "concerning" that in mice semax "potentiated amphetamine-induced dopamine release in the striatum".1

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3 min
Bioavailability
95%
Typical dose
200–600 mcg
Route
Nasal, SubQ
Time to peak
~3 min

The app lists a half-life of about 3 minutes and a time to peak of about 3 minutes. None of the references below gives a half-life for Semax. FDA states: "We were not able to find pharmacokinetic studies in humans following exposure to semax (free base) or semax acetate via any ROA" (ROA is FDA's abbreviation for route of administration), and that it "did not identify studies assessing the pharmacokinetic profile of semax delivered via the SC ROA".1

Table 4.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the references
Half-lifeAbout 3 minutesNo half-life value reported. FDA's summary: "In-vitro studies reported that semax is quickly hydrolyzed in rat blood and brain tissue".1
Time to peakAbout 3 minutesRats given 50 µg/kg intranasally: 0.093% of the introduced radioactivity per gram was in brain 2 minutes after dosing, 80% of it Semax.5 FDA gives the highest brain concentration at 2 minutes, the first sampling time, at about 0.072% of the dose.1 The two figures are given as published; the sources do not reconcile them.
Bioavailability95%No bioavailability figure reported. Rat brain delivery: about 0.072% of the dose intranasally and about 0.005% intravenously (50 µg/kg each), per FDA.1
RoutesNasal, SubQFDA: "The only ROA discussed in the literature was intranasal" and "There are no safety data for semax (free base) and semax acetate administered by the proposed SC ROA".1
DurationAbout 8 hoursAsmarin and colleagues, 1997: stimulation of operative memory and attention, resistance to hypoxia and brain circulation in animals and people "over prolonged period (20-24 h after intranasal administration in doses 0.015-0.050 mg/kg)".6

Potaman and colleagues (Institute of Molecular Genetics, USSR Academy of Sciences), 1991, found in rat blood and serum that "bestatin-sensitive aminopeptidase" accounted for "about one third to one half of the serum degrading activity", cleaving the first and second N-terminal residues, Met and Glu, to produce "relatively stable intermediates", and that Semax was "more stable than ACTH(4-10)" against other enzymes.7 Shevchenko and colleagues, 2006, report rapid enzymatic degradation in rats, with the tripeptide Pro-Gly-Pro "prevailing in biological samples".5

5

Human studies

A query of PubMed on 16 November 2026 for semax in titles or summary text returned 210 records; 4 carry the clinical trial publication type and 1 the randomized controlled trial type. A query of ClinicalTrials.gov for the term semax on the same date returned 0 studies.

FDA, limiting its safety assessment to the intranasal route, counts the human exposure in the literature it reviewed: "semax has been administered to 33-47 healthy adults", "69 adults with medical conditions" and "451 children with either depression or tics/Tourette Syndrome".1

In Ivanikov and colleagues' 2002 report, FDA notes, "the semax used in this study was synthesized at the Laboratory of Regulatory Peptides, Institute of Molecular Genetics, Russian Academy of Sciences", and the authors write that clinical studies of Semax with usual antiulcer drugs "are needed".1,8

Several of the reports share an author. Miasoedov (also spelled Myasoedov) is an author of Asmarin 19976, Gusev 19979, Ivanikov 20028, Serdiuk 200714 and Lebedeva 201815, and of the rat and laboratory reports by Dolotov2, Agapova3, Kost4 and Shevchenko5; Nezavibat'ko is an author of Asmarin 1997, Gusev 1997 and Potaman 19917. The PubMed records of Dolotov 2006 and Agapova 2007 carry the type "Research Support, Non-U.S. Gov't"; no record names a funder or sponsor.

Table 5.1Human studies10 rows
Study and yearDesignPeopleDose and lengthMain result
Gusev and colleagues, 19979Controlled clinical trial; conventional therapy as comparison30 patients with acute hemispheric ischemic stroke; 80 controls12 mg daily (moderate strokes) or 18 mg daily (severe); courses of 5 and 10 daysSemax "had some influence on the rate of restoration of the damaged neurological functions"
Gusev and colleagues, 201810Clinical trial; semax and no-semax subgroups within early or late rehabilitation110 patients after ischemic stroke6000 mcg/day, 2 courses of 10 days with a 20-day intervalPlasma BDNF rose and "remained high during the whole study period"; Barthel improvement accelerated with Semax and high BDNF (authors report correlations; no effect sizes in the record)
Gusev and colleagues, 200511Comparative, evaluation study; comparator not given in the record187 patients with cerebrovascular insufficiencyNot given in the record"significant clinical improvement, stabilization of the disease progress and reduced a risk of stroke and transitory ischemic attacks"; "well tolerated"
Polunin and colleagues, 200012Controlled clinical trial; three groups, group 3 controlPatients with optic nerve disease, added to basic neurotrophic and anti-inflammatory therapyNasal drops (group 1) or endonasal electrophoresis (group 2); dose not given"a favorable impact on the intensity and rate of recovery and improved the visual functions"
Ivanikov and colleagues, 20028Semax plus basic therapy (omeprazole, De-Nol, Solcoseril) vs basic therapy alone, per FDA's table1Refractory peptic ulcers; FDA's table gives 32 adults with peptic ulcer, the record gives no n per arm1% solution, 2 to 4 drops 3 times a day for 10 days, intranasalUlcer healing on day 14: 89.5% with Semax vs 30.8% in the control group
Alekseeva and colleagues, 199913Comparative study73 patients with posthypoxic encephalopathy, 14 in a persistent vegetative stateNot given in the recordEffective in patients with mnestic disorders; effect potentiated by oxiterm and by supraorbital electrophoresis; EEG paroxysmal activity "in some cases" after injection; comparator and numbers not given
Serdiuk and colleagues, 200714Open-label trial in sequential groups; PubMed lists the randomized controlled trial type27 patients with motor neuron disease12 mg daily intranasal, two 10-day courses with a 2-week breakNo influence on chronic partial denervation or clinical estimates; total quality of life estimate improved, maximal on day 10
Lebedeva and colleagues, 201815Two groups; resting-state fMRI before and 5 and 20 minutes after24 healthy volunteers (11 men, 13 women, aged 43.9±9.5 years); FDA: unclear if the same subjects were used in Lebedeva 2018 and Panikratova 20201Intranasal 1% Semax (14) or placebo (10); FDA's table lists 1.2 mg; number of doses not stated1Larger default mode network rostral subcomponent in the Semax group than in controls
Dontsova, 201516Conventional therapy vs the same plus Semax118 patients with psoriasis and metabolic syndrome (58 and 60)0.1% solution intranasally, "600 mg/day" as printed in the record, 10 daysTotal cholesterol, triglycerides and LDL cholesterol fell and HDL cholesterol rose with Semax; standard treatment produced no statistically significant effect
Koroleva and colleagues, 1996, as described by FDA1Single dose, no blinding, no control group (FDA's description)12 adults with migraine; 25 with trigeminal neuralgia0.5 mg/kg intranasal, onceMigraine: headache pain ceased in 4 of 12; typical trigeminal neuralgia (16): no changes; dental plexalgia (9): pain resolved in 6; FDA: overall no reduction in frequency or duration of pain attacks, rating scale not described

FDA writes of the references it used for safety information that "In several of the references, semax was administered concomitantly with other medications or therapies", "making it difficult to determine the contribution of semax to any effects seen", and that three of the references were professional society meeting items.1

Deeper analysis: FDA's evaluation, July 2026

FDA's briefing is dated 11 May 2026 and was written by FDA staff for the Pharmacy Compounding Advisory Committee. It evaluates semax (free base) and semax acetate after two nominations, from Wells Pharmacy Network and LDT Health Solutions, that were later withdrawn; FDA states it "is evaluating the substances at its discretion", for "cerebral ischemia, migraine and trigeminal neuralgia".1 Its authors are FDA staff, and the briefing names no outside funder or sponsor for the evaluation.1

For cerebral ischemia the only item FDA could use was a professional society meeting item by Cherkasova and colleagues, 2002, in which "An unknown number of human subjects with chronic ischemic brain disease received intranasal semax 600 mg daily for 10 days"; FDA says no full published article could be located and that it did not report clinical function before and after treatment.1

For migraine and trigeminal neuralgia FDA assessed Koroleva and colleagues, 1996. In 12 adults with migraine given one 0.5 mg/kg intranasal dose, FDA reports that "total MPST score decreased from 78% before semax to 32%" and that "Four subjects out of twelve (33%) reported cessation of headache pain", while in 8 the effect was weaker.1 In 16 people with typical trigeminal neuralgia there were no changes in the characteristics of pain or in sensation or pain thresholds; in 9 with dental plexalgia, "pain resolved in 6 subjects and 3 subjects reported a decrease in pain severity", although FDA adds that "MPST results showed that overall, there was no reduction in frequency of pain attacks, duration of pain attacks, and differences in sensory characteristics of pain".1 On trigeminal somatosensory evoked potentials (TSEP), the authors concluded that "no significant changes in TSEP were observed after a single intranasal administration of semax", which "indicates that semax does not exhibit analgesic activity by itself".1 FDA lists "the small sample size, no blinding, no control group", no reported scores or standard deviations, no description of the rating scale (the modified pain sensitivity test, MPST), and writes that "it appears that the authors assigned arbitrary units when they discussed their findings" and that the clinical relevance is unclear.1 FDA concluded for each use that the results came from one small, uncontrolled, open-label study that "showed that semax was not effective in resolving" pain for the majority of subjects.1

Deeper analysis: Gusev and colleagues, 1997, stroke

Gusev and colleagues gave Semax within combined intensive therapy to 30 patients in the acute period of hemispheric ischemic stroke and compared them with 80 controls with strokes "analogous in severity and location" who received conventional therapy.9 The record reports that Semax "had some influence on the rate of restoration of the damaged neurological functions" in terms of "increasing the regress of general cerebral and focal, especially motor disorders", without numerical effect sizes or p-values, and gives 12 mg and 18 mg daily as the "most effective daily doses".9 The record names no funder, conflict-of-interest statement or limitations, and does not say how patients were assigned to Semax or control.9

Deeper analysis: Gusev and colleagues, 2018, after stroke

The authors, from the Pirogov Russian National Research Medical University and a Moscow rehabilitation centre, examined 110 patients after ischemic stroke in early (89±9 days) and late (214±22 days) rehabilitation groups, each split into Semax and no-Semax subgroups.10 They measured plasma BDNF, motor performance on the British Medical Research Council scale and the Barthel index.10 They write that "Administration of semax and high BDNF levels accelerated the improvement and ameliorated the final outcome of Barthel score index" and that in the no-Semax subgroups high BDNF correlated positively with early rehabilitation.10 The record reports correlations, including a positive one between BDNF plasma levels and Barthel score, and gives no effect sizes, p-values, funder, conflict-of-interest statement or limitations, and does not say whether assignment was random.10

6

Doses reported in studies

The app's typical dose is 200 to 600 mcg. Among the doses in the table, only the 0.25 mg single dose in FDA's table for Kaplan and colleagues, 1996 lies within that range; the other human doses in the table are larger, per day or per kilogram.

Table 6.1Doses reported in studies5 rows
SourceWhoDose and routeLengthNote
Kaplan and colleagues, 1996, FDA table119 healthy adult males1 mg (16 mcg/kg) daily or 0.25 mg once, intranasal2 days, or onceFDA: adverse events not discussed
Koroleva and colleagues, 1996, FDA1Adults with migraine or trigeminal neuralgia0.5 mg/kg intranasalOnceFDA: the authors reported no adverse events; see the FDA analysis above
Gusev and colleagues, 19979Acute ischemic stroke12 mg or 18 mg daily5 and 10 daysThe record's wording is "most effective daily doses"
Gusev and colleagues, 201810After ischemic stroke6000 mcg/day2 courses of 10 days, 20-day intervalRoute not stated in the record
Serdiuk and colleagues, 200714Motor neuron disease12 mg daily, intranasal, 1% solution2 courses of 10 days, 2-week breakOpen-label

FDA searched its adverse event reporting system through 3 December 2025: "The search retrieved one FAERS report", a consumer report of "ocular pain and eye burning after using Semax 0.1% nasal drops purchased online", with hospitalization and eye pain not resolved when reported in May 2025.1 FDA's literature searches "did not identify literature case reports of AEs in humans".1 FDA adds that compounders generally do not report adverse events to it, so it may not be aware of events.1

Of the clinical references FDA tabulated, "In one reference the authors report that no AEs were observed and in the other references AEs were not discussed".1 Gusev and colleagues, 2005, wrote that Semax "is well tolerated by patients" with "minor percent of side-effects", giving no figures in the record.11 Asmarin and colleagues, 1997, in a review of 15 years of experience in the design and study of Semax, wrote, with no numbers in the record, that "in no case it produced negative side actions".6 Alekseeva and colleagues, 1999, report EEG paroxysmal activity "in some cases" after injection and call for monitoring at the first injection.13

FDA states that the possible antithrombotic properties discussed in the 2002 meeting item by Cherkasova and colleagues, which covered both rats and humans, mean this "raises concern about the risk of bleeding, particularly in certain populations at risk for bleeding", and that it is "concerned about their potential for immunogenicity when administered by an injection ROA as proposed", noting that no clinical immunogenicity studies were identified.1

The app lists no markers. In the human reports, plasma BDNF rose after Semax in patients after stroke (Gusev and colleagues, 2018), and serum total cholesterol, triglycerides and LDL cholesterol fell in patients with psoriasis and metabolic syndrome who received Semax in addition to conventional therapy (Dontsova, 2015).10,16 Separately, FDA describes a 2002 meeting item by Cherkasova and colleagues in which semax was given to both rats and humans: its authors "measured labs related to blood clotting" but "do not specify if these labs were done in the animal or human subjects" and "do not provide full results for these lab values".1

FDA's safety-risk page, current as of 22 April 2026, lists "Semax (heptapeptide)" under "Bulk drug substances nominated but withdrawn" with the statements that compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities" and that "FDA has no, or limited, safety-related information for proposed routes of administration".17 FDA's reviewers wrote that "the evaluation criteria weigh against placing both semax (free base) and semax acetate on the list of bulk drug substances" for 503A compounding.1 The advisory committee met on 23 and 24 July 2026; Healio reports that "the committee voted 8-5-1 for semax in both acetate and free-base forms", which is 8 in favour, 5 against and 1 abstention, and that "Most of the 'no' voters cited safety concerns".18 AJMC reports that the panel's votes were "overriding career scientists who had recommended against including any of the 7", that FDA scientists "uniformly opposed adding any of the 7 substances", that the reconstituted roster "drew scrutiny for including more health professionals who prescribe, produce, or promote peptides than prior iterations of the panel", and that FDA "must still decide whether to accept the committee's nonbinding recommendations".19

On compounding history FDA writes: "No outsourcing facility has reported compounding drug products containing semax since 2019" and "No studies were found in which semax was used as a compounded drug product".1

The World Anti-Doping Agency's 2026 Prohibited List does not contain the word Semax. Its class S2.2.2 reads "Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide", in a section whose listed substances "and other substances with similar chemical structure or similar biological effect(s), are prohibited" at all times.20 The sources do not state whether S2.2.2 covers Semax.20

10

What is not known

FDA found no pharmacokinetic study of semax in humans by any route, no safety data for the subcutaneous route, and "did not identify acute toxicity studies of semax" or "nonclinical developmental and reproductive studies of semax".1 It found no nonclinical study showing "whether semax has reinforcing and addictive properties".1 The references above give no half-life, no bioavailability and no peak time for Semax in people, so the app's figures for those are not sourced here.1

What is the half-life of Semax?

No half-life for Semax is reported in the references; the app lists about 3 minutes. FDA found no pharmacokinetic study in humans.1 In rats, radioactivity from labelled Semax was measured in brain 2 minutes after intranasal dosing, with rapid enzymatic degradation reported.5

Is Semax FDA approved?

No: FDA states that neither semax (free base) nor semax acetate is a component of an FDA-approved drug.1

What did the FDA advisory committee decide about Semax?

The Pharmacy Compounding Advisory Committee voted 8-5-1 for semax in both acetate and free-base forms on 24 July 2026 (8 in favour, 5 against, 1 abstention; Healio reports that most of the "no" voters cited safety concerns), after FDA's reviewers had concluded that the criteria weigh against listing it.18,19,1 The votes were nonbinding, and FDA must still decide whether to accept them.19

Is Semax banned by WADA?

The 2026 WADA Prohibited List does not name Semax.20 Its class S2.2.2 names "Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide", and the sources do not state whether it covers Semax.20

Which routes of administration have been studied in people?

FDA found intranasal use in the human literature and no subcutaneous data: "The only ROA discussed in the literature was intranasal".1 One 1999 Russian record, by Alekseeva and colleagues, mentions an injection,13 a 2000 report by Polunin and colleagues gave Semax as nasal drops or by endonasal electrophoresis,12 and the record of Gusev and colleagues, 2018, does not state a route.10

What side effects of Semax have been reported?

FDA's adverse event search through 3 December 2025 retrieved one report, of eye pain and burning after nasal drops bought online, with hospitalization.1 In the clinical references FDA tabulated, one reported no adverse events and the others did not discuss them.1

Does Semax improve memory and attention in people?

FDA's reviewers concluded that evidence of effectiveness was insufficient for the three uses they assessed, and note that one review's human references on neuroprotective and nootropic effects are in healthy adults or written in Russian.1 Asmarin and colleagues, 1997, in a review of 15 years of experience in the design and study of Semax, state that Semax "significantly improves memory and attention in healthy men under extreme conditions of activities", with no numbers in the record.6

Has Semax been tested in people?

Yes: FDA counts "33-47 healthy adults", "69 adults with medical conditions" and "451 children with either depression or tics/Tourette Syndrome" given intranasal semax in the literature it reviewed, and notes that three of the references were meeting items and that in several semax was given with other medications or therapies.1 FDA concluded that the evidence for the three uses it assessed was insufficient.1

13

References

  1. US Food and Drug Administration. Evaluation of Semax-related bulk drug substances (Semax (free base) and Semax acetate) for inclusion on the 503A bulk drug substances list. Briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026 (dated 11 May 2026). FDA briefing document
  2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006. PMID 16996037
  3. Agapova TY, Agniullin YV, Shadrina MI, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neurosci Lett 2007. PMID 17353092
  4. Kost NV, Sokolov OIu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim 2001. PMID 11443939
  5. Shevchenko KV, Nagaev IIu, Alfeeva LIu, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim 2006. PMID 16523722
  6. Asmarin IP, Nezavibat'ko VN, Miasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova 1997. PMID 9173745
  7. Potaman VN, Alfeeva LY, Kamensky AA, Levitzkaya NG, Nezavibatko VN. N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. Biochem Biophys Res Commun 1991. PMID 1851003
  8. Ivanikov IO, Brekhova ME, Samonina GE, Myasoedov NF, Ashmarin IP. Therapy of peptic ulcer with semax peptide. Bull Exp Biol Med 2002. PMID 12459874
  9. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997. PMID 11517472
  10. Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018. PMID 29798983
  11. Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova 2005. PMID 15792140
  12. Polunin GS, Nurieva SM, Baiandin DL, et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol 2000. PMID 10741256
  13. Alekseeva GV, Bottaev NA, Goroshkova VV. Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesteziol Reanimatol 1999. PMID 10199046
  14. Serdiuk AV, Levitskii GN, Miasoedov NF, Skvortsova VI. The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Zh Nevrol Psikhiatr Im S S Korsakova 2007. PMID 18379501
  15. Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med 2018. PMID 30225715
  16. Dontsova EV. Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis. Eksp Klin Farmakol 2015. PMID 27051926
  17. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). FDA safety-risk page
  18. Bascom E. FDA committee recommends looser restrictions for several peptides. Healio, 24 July 2026. Healio report
  19. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC, 31 July 2026. AJMC report
  20. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026